Atovaquone and proguanil hydrochloride: A review of nonclinical studies

Journal of Travel Medicine

Volumn 6, Issue SUPPL. 1, 1999, Pages

  Pudney, Mary ^a   Gutteridge, Win ^b   Zeman, Anton ^c   Dickins, Maurice ^a   Woolley, Joseph L ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Spec Prog Res/Train Trop Dis   (Switzerland)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYCLOGUANIL; PROGUANIL;

ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HYPERSALIVATION; LETHAL DOSE; MALARIA; MEDICAL LITERATURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; DISEASE OUTBREAKS; DOGS; DRUG COMBINATIONS; HUMANS; MALARIA; MICE; MODELS, ANIMAL; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PROGUANIL; RATS; TRAVEL;

EID: 0033008409     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hudson AT, Dickins M, Ginger CD, et al. 566C80; a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991; 17:427-435.
2. Basco LK, Ramiliarisoa O, Le Bras J. In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1995; 53:388-391.
3. Gay F, Bustos D, Traore B, et al. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 1997; 56:315-317.
4. Davies CS, Pudney M, Matthews PJ, Sinden RE. The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats. Acta Leidensia 1989; 58:115-128.
5. Davies CS, Suhrbier AS, Winger LA, Sinden RE. Improved techniques for the culture of the liver stages of Plasmodium berghei and their relevance to the study of causal prophylactic drugs. Acta Leidensia 1989; 58:97-113.
6. Fleck SL, Pudney M, Sinden RE. The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Trans R Soc Trop Med 1996; 90:309-312.
7. Fowler RE, Sinden RE, Pudney M. Inhibitory activity of the antimalarial atovaquone (566C80) against ookinetes, oocysts, and sporozoites of Plasmodium berghei. J Parasitol 1995; 81:452-458.
8. Fowler RE, Billingsley PF, Pudney M, Sinden RE. Inhibitory action of the anti-malarial compound atovaquone (566C80) against Plasmodium berghei ANKA in the mosquito, Anopheles stephensi. Parasitology 1994; 108:383-388.
9. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992; 43:1545-1553.
10. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997; 272:3961-3966.
11. Glaxo Wellcome, data on file.
12. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-66.
13. Wilson CM, LeBlanc SB, Kyle DE. Atovaquone resistance in clinical isolates of Plasmodium falciparum is associated with point mutations in the cytochrome b gene. Molecular Basis for Drug Resistance in Bacteria, Parasites and Fungi: The Keystone Symposia on Molecular Biology 1996. Park City, UT, 11-17 March 1996.
14. Watkins WM, Sixsmith DG, Chulay JD. The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 1984; 78:273-278.
15. Khan B, Omar S, Kanyara JN, et al. Antifolate drug resistance and point mutations in Plasmodium falciparum in Kenya. Trans R Soc Trop Med 1997; 91:456-460.
16. Peters W, Davies EE, Robinson BL. The chemotherapy of rodent malaria, XXIII. Causal prophylaxis, part II: practical experience with Plasmodium yoelii nigeriensis in drug screening. Ann Trop Med Parasitol 1975; 69:311-328.
17. Fairley NH. Researches on paludrine (M.4888) in malaria. An experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, Australia. Trans R Soc Trop Med 1946; 40:105-151.
18. Eriksson B, Courtier B. Bjorkman A, et al. Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoelii in vitro. Trans R Soc Trop Med 1991; 85:725-726.
19. Bruce-Chwatt LJ. Evaluation of synthetic anitmalarial drugs in children from a hyperendemic area in West Africa. Trans R Soc Trop Med 1951; 44:563-592.
20. Ferone R. Dihydrofolate reductase inhibitors. In: Peters W, Richards WHG, eds. Handbook of experimental pharmacology Vol 68/II:antimalarial drugs. New York: Springer-Verlag, 1984: 207-221.
21. Fidock DA, Wellems TE. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci 1997; 94:10931-10936.
22. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80:373-381.
23. Butler R, Davey DG, Spinks A. A preliminary report of the toxicity and the associated blood concentrations of paludrine in laboratory animals. Br J Pharmacol 1947; 2:181-188.
24. 5-isopropylbiguanide (paludrine). Pharmacol Exp Ther 1947; 90:233-253.
25. Birkett DJ, Rees D, Andersson T, et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37:413-420.
26. Funck-Brentano C, Becquemont L, Lenevu A, et al. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280:730-738.
27. Cutting W. Anti-fertility effects of biguanides. Antibiot Chemother 1962; 12:671-675.
28. Shepard TH. Catalog of teratogenic agents. 7th Ed. Baltimore: Johns Hopkins University Press, 1992.
29. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone™ (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999; 60:533-541.
30. Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 1995; 50:176-196.
31. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
32. Parke DV, Ioannides C. Role of cytochromes P-450 in mouse liver tumor production. In: Stevenson DE, Popp JA, Ward JM, et al., eds. Mouse liver carcinogenesis: mechanisms and species comparisons. New York: Wiley-Liss, 1990: 215-230.